Articles from Inflammasome Therapeutics

Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has signed a contract with The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital to design a new Healey ALS MyMatch trial evaluating oral Kamuvudine-9 (K9) in individuals with amyotrophic lateral sclerosis (ALS).

Inflammasome Therapeutics (https://www.inflam.com), is a clinical-stage biotech company developing a new class of inflammasome inhibitors called Kamuvudines for ophthalmic and neurological conditions. Today, the company announced that the first of these drugs, K8, delivered via a sustained release intraocular implant for the treatment of Geographic Atrophy (GA), reduced GA lesion area growth by more than 50% following three months of treatment among an initial cohort of patients. This first human clinical trial for the drug is evaluating K8 in a multicenter 30-patient, six-month, safety and dose-escalation trial with three cohorts (NCT06164587). Patients with bilateral GA receive low, medium or high dose implants at baseline and three months in one eye, and untreated eyes serve as controls.

Inflammasome Therapeutics (https://www.inflam.com/), a clinical-stage biotech company developing novel, first-in-class dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, today announced positive topline 3-month data from a clinical trial of its K8 implant in patients with geographic atrophy (GA), the most serious form of dry age-related macular degeneration (AMD). Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky (NCT06164587).

Inflammasome Therapeutics, a private company, has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug K9, which has application in the treatment of multiple neuroinflammatory, degenerative diseases (such as Alzheimer’s, MS, ALS, Parkinson’s, geographic atrophy) and autoimmune diseases such as lupus and thyroid eye disease.

Inflammasome Therapeutics (https://www.inflam.com), a private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a first-in-class clinical trial for dry AMD. The Phase 1 trial (ClinicalTrials.gov ID NCT06164587) is sponsored by the University of Kentucky and expected to enroll up to five patients with GA due to age-related macular degeneration (AMD).

Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage, private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a Phase 1 study of one of the company’s novel compounds in the treatment of diabetic macular edema (DME).

Inflammasome Therapeutics (https://inflam.com), a private company, developing a new class of inflammasome inhibitor drugs called Kamuvudines as therapies for prevalent, degenerative diseases, announced the FDA has granted approval for the opening of a Phase 1/2 clinical trial of the company’s drug for the treatment of Geographic Atrophy (GA), the most severe form of dry AMD. This is the first clinical trial of an inflammasome inhibitor to treat GA. Paul Ashton, CEO of Inflammasome Therapeutics, said, “This is a very important milestone for the company, as it represents the initial clinical trial of several planned for our Kamuvudines in a number of other neuroinflammatory conditions, including Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD) and Multiple Sclerosis (MS).

Inflammasome Therapeutics (https://inflam.com), a private company developing therapies for prevalent, degenerative diseases, said today that research published in Science Immunology (https://www.science.org/doi/10.1126/sciimmunol.abi4493) “DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs”, uncovers a previously unrecognized mechanism by which NLRC4 combines with NLRP3 to form activated inflammasomes that trigger causes of active disease in macular degeneration and lupus.

Paul Ashton, president and CEO of Inflammasome Therapeutics (https://inflam.com), a private company developing therapies for prevalent, degenerative diseases, will be one of the featured speakers at the Inflammasome Therapeutics Summit. This digital event, November 16-18, marks its third year as the only industry-dedicated forum that focuses specifically on inflammasome regulation and novel inflammasome therapeutics.

Inflammasome Therapeutics (https://inflam.com), a private company developing therapies for prevalent, degenerative diseases, reported new research conducted by a team of scientists led by Inflammasome’s co-founder Dr. Jayakrishna Ambati, and published today in Science Advances https://www.science.org/doi/10.1126/sciadv.abj3658 on Geographic Atrophy (GA), the most severe form of dry Age-related Macular Degeneration (AMD). In GA an area of the retinal pigmented epithelium (RPE, a layer of cells in the retina) becomes atrophied and the overlying sensory retina dies. Over time this area slowly spreads leading to blindness. It has been previously reported that Alu RNA is over expressed in the retinas of individuals with this condition. The paper confirms that in human eyes Alu RNA/cDNA conversion triggers inflammasome activity and resulting retinal cell death. Further, the paper shows that this process is confined to the rim of the lesion, indicating a potential for treatments to halt inflammasome activation and the progression of this disease to otherwise normal retina.

Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases and sustained-release drug delivery systems, announced it has been awarded a second grant from the Bill & Melinda Gates Foundation. The new $1.3 million grant will be used to develop a 12-month bioerodible implant for women to provide prevention from HIV infection coupled with birth control. According to a Kaiser Family Foundation report released in March 2021, women represent more than half (55%) of all adults (15-49) living with HIV worldwide, and HIV (along with complications related to pregnancy) is the leading cause of death among women of reproductive age.

Inflammasome Therapeutics (https://www.inflam.com), a private company developing therapies for prevalent, degenerative diseases, reported newly published research continues to confirm the potential of the company’s proprietary Kamuvudines, to be an effective treatment for geographic atrophy (GA), a severe and untreatable form of age-related macular degeneration (AMD) that causes 20% of legal blindness in the US.